Skip to main content
Advertisement
Advertisement

AMLX

AMLX logo

Amylyx Pharmaceuticals, Inc. Common Stock

30.61
USD
Sponsored
-2.39
-7.26%
Sep 23, 15:59 UTC -4
Closed
exchange

After-Market

30.62

+0.02
+0.05%

AMLX Earnings Reports

Positive Surprise Ratio

AMLX beat 8 of 19 last estimates.

42%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.39
Implied change from Q2 26 (Revenue/ EPS)
--
/
--
Implied change from Q3 25 (Revenue/ EPS)
--
/
+5.41%

Amylyx Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Aug 06, 2026, AMLX reported earnings of -0.39 USD per share (EPS) for Q2 26, missing the estimate of -0.36 USD, resulting in a -5.95% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +10.71% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.39 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Champions Oncology, Inc.
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.01
Actual
-$0.03
Surprise
-194.12%
logo
PharmaCyte Biotech, Inc. Common Stock
Report Date
Sep 14, 2026 For Q1 27
Estimate
-
Actual
-$0.54
Surprise
-
FAQ
For Q2 2026, Amylyx Pharmaceuticals, Inc. Common Stock reported EPS of -$0.39, missing estimates by -5.95%, and revenue of $0.00, 0% as expectations.
The stock price moved up 10.71%, changed from $21.85 before the earnings release to $24.19 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on 6 analysts, Amylyx Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.39 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement